Helus Pharma to Participate in the Jefferies Global Healthcare Conference in New York Medical Device Investing
Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026 Life Science Investing
Axsome Therapeutics Partners with the Headache Alliance to Highlight the Impact of Migraine During Migraine and Headache Awareness Month Life Science Investing
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Supplemental New Drug Application for Camzyos to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy Life Science Investing
Bristol Myers Squibb Announces Opdivo® in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma Life Science Investing
Defence Therapeutics Appoints Antibody Drug Conjugates Pioneer Dr. John Lambert to Its Board of Directors Life Science Investing
UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol Phase 3 Study Results in Systemic Lupus Erythematosus Life Science Investing
Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China Life Science Investing
Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer Pharmaceutical Investing
Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years Life Science Investing
